Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

被引：0

作者：

Borghaei, H. ^{[1
]}

Langer, C. J. ^{[2
]}

Gadgeel, S. ^{[3
]}

Papadimitrakopoulou, V. A. ^{[4
]}

Patnaik, A. ^{[5
]}

Powell, S. F. ^{[6
]}

Gentzler, R. D. ^{[7
]}

Martins, R. G. ^{[8
]}

Stevenson, J. P. ^{[9
]}

Jalal, S. I. ^{[10
]}

Panwalkar, A. ^{[11
]}

Yang, J. C-H. ^{[12
]}

Gubens, M. ^{[13
]}

Sequist, L. ^{[14
]}

Awad, M. M. ^{[15
]}

Fiore, J. ^{[16
]}

Saraf, S. ^{[16
]}

Raftopoulos, H. ^{[16
]}

Gandhi, L. ^{[17
]}

机构：

[1] Fox Chase Canc Ctr, Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[2] Abramson Canc Ctr, Dept Med, Philadelphia, PA USA

[3] Karmanos Canc Inst, Thorac Oncol, Detroit, MI USA

[4] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Oncol, Houston, TX 77030 USA

[5] South Texas Accelerated Res Therapeut, Clin Res, San Antonio, TX USA

[6] Sanford Heath, Oncol, Sioux Falls, SD USA

[7] Univ Virginia, Hematol Oncol, Charlottesville, VA USA

[8] Univ Washington, Med, Seattle, WA 98195 USA

[9] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[10] Indiana Univ Sch Med, Internal Med, Indianapolis, IN 46202 USA

[11] Sanford Roger Maris Canc Ctr, Hematol Oncol, Fargo, ND USA

[12] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[13] Univ Calif San Francisco, Med Oncol, San Francisco, CA 94143 USA

[14] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA

[15] Dana Farber Canc Inst, Thorac Oncol, Boston, MA 02115 USA

[16] Merck & Co Inc, Clin Res, Kenilworth, NJ USA

[17] NYU Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA49

引用

页数：2

共 50 条

[41] A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC)
Dy, G. K.
Mandrekar, S. J.
Nelson, G. D.
Ross, H. J.
Ansari, R. H.
Lyss, A. P.
Stella, P. J.
Schild, S. E.
Molina, J. R.
Adjei, A. A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[42] Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population.
Balar, Arjun Vasant
Castellano, Daniel E.
O'Donnell, Peter H.
Grivas, Petros
Vuky, Jacquiline
Powles, Thomas
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[43] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
Powles, Thomas
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem Airatovich
Hawkins, Robert E.
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris Yakovlevich
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio Jobim
Borchiellini, Delphine
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[44] First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.
Loriot, Yohann
Grivas, Petros
De Wit, Ronald
Balar, Arjun Vasant
Siefker-Radtke, Arlene O.
Zolnierek, Jakub
Csoszi, Tibor
Shin, Sang Joon
Park, Se Hoon
Atduev, Vagif
Gumus, Mahmut
Su, Yu-Li
Karaca, Saziye Burcak
Cutuli, Hernan
Sendur, Mehmet Nahit
Jia, Calvin
O'Hara, Karen
Franco, Sonia
Matsubara, Nobuaki
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[45] A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC): Preliminary results.
Garin, A
Manikhas, A
Biakhov, M
Chezhin, M
Ivanchenko, T
Krejcy, K
Karaseva, V
Tjuyandin, S
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 51S - 51S
[46] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Bang, Yung-Jue
Kang, Yoon-Koo
Catenacci, Daniel V.
Muro, Kei
Fuchs, Charles S.
Geva, Ravit
Hara, Hiroki
Golan, Talia
Garrido, Marcelo
Jalal, Shadia I.
Borg, Christophe
Doi, Toshihiko
Yoon, Harry H.
Savage, Mary J.
Wang, Jiangdian
Dalal, Rita P.
Shah, Sukrut
Wainberg, Zev A.
Chung, Hyun Cheol
GASTRIC CANCER, 2019, 22 (04) : 828 - 837
[47] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Yung-Jue Bang
Yoon-Koo Kang
Daniel V. Catenacci
Kei Muro
Charles S. Fuchs
Ravit Geva
Hiroki Hara
Talia Golan
Marcelo Garrido
Shadia I. Jalal
Christophe Borg
Toshihiko Doi
Harry H. Yoon
Mary J. Savage
Jiangdian Wang
Rita P. Dalal
Sukrut Shah
Zev A. Wainberg
Hyun Cheol Chung
Gastric Cancer, 2019, 22 : 828 - 837
[48] Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
Tabernero, J.
Van Cussem, E.
Bang, Y.
Fuchs, C.
Wyrwicz, L.
Lee, K.
Kudaba, I.
Garrido, M.
Chung, C.
Salguero, C. Castro
Mansoor, W.
Braghiroli, M.
Goekkurt, E.
Chao, J.
Wainberg, Z.
Kher, U.
Shah, S.
Karg, S.
Shitara, K.
ANNALS OF ONCOLOGY, 2019, 30 : 152 - +
[49] First-line pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study
Qin, S.
Liang, T.
Gu, S.
Gou, H.
Peng, C.
Pan, Y.
Song, T.
Su, H.
Cao, K.
Liang, H.
Ying, J.
Geng, Z.
Yu, W.
Zhao, H.
Bai, Y.
Hao, C-Y.
Wang, W.
Li, N.
Malhotra, U.
Ren, Z.
ANNALS OF ONCOLOGY, 2024, 35 : S230 - S230
[50] Pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
Rha, Sun Young
Wyrwicz, Lucjan S.
Weber, Patricio Eduardo Yanez
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Rivera, Fernando
Alves, Gustavo Vasconcelos
Garrido, Marcelo
Shiu, Kai-Keen
Fernandez, Manuel Gonzalez
Li, Jin
Lowery, Maeve Aine
Cil, Timucin
Cruz, Felipe Melo
Oh, Do-Youn
Yin, Lina
Bordia, Sonal
Bhagia, Pooja
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →